ASCO 2025
ASCO 2025
ASCO 2025: Phase 3, Randomized, Placebo-Controlled Clinical Trial of CAN-2409 + Prodrug in Combination with Standard of Care External Beam Radiation for Newly Diagnosed Localized Prostate Cancer
- Details
(UroToday.com) The 2025 ASCO annual meeting featured a prostate cancer oral abstract session and a presentation by Dr. Theodore DeWeese discussing a phase 3, randomized, placebo-controlled clinical trial of CAN-2409 + Prodrug in combination with standard of care external beam radiation for newly diagnosed localized prostate cancer. There is currently an unmet need in localized prostate cancer, with approximately 1.4 million new cases of prostate cancer in 2020 globally. The following figure shows the incidence in the United States:
ASCO 2025: A Multicenter, Randomized, Phase 2, Investigator-Initiated ETCTN Trial of Olaparib + Radium-223 vs. Radium-223 in Men with Castration-Resistant Prostate Cancer (CRPC) with Bone Metastases (BM) (COMRADE): Initial Efficacy and Biomarker Analysis
- Details
(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL, was host to the Oral Abstract Session: Genitourinary Cancer—Prostate, Testicular, and Penile. Dr. Rana McKay presented a multicenter, randomized, phase 2, investigator-initiated ETCTN trial of olaparib + radium-223 vs. radium-223 in men with castration-resistant prostate cancer with bone metastases (COMRADE): Initial efficacy and biomarker analysis.
ASCO 2025: Health-Related Quality of Life (HRQoL) Outcomes with Darolutamide in the Phase 3 ARANOTE Trial
- Details
(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL, was host to the Oral Abstract Session: Genitourinary Cancer—Prostate, Testicular, and Penile. Dr. Alicia Morgans presented the Health-related quality of life (HRQoL) outcomes with darolutamide in the phase 3 ARANOTE trial.
ASCO 2025: Prognostic Significance of PSA>0.2 After 6-12 Months Treatment for mHSPC Intensified by ARPI: A Multinational Real-World Analysis of the IRONMAN Registry
- Details
(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL, was host to the Oral Abstract Session: Genitourinary Cancer—Prostate, Testicular, and Penile. Dr. Michael Ong Presented data on the Prognostic significance of PSA>0.2 after 6-12 months treatment for metastatic hormone-sensitive prostate cancer (mHSPC) intensified by androgen-receptor pathway inhibitors (ARPI) from A multinational real-world analysis of the IRONMAN registry.
ASCO 2025: How to Get Lutetium-177 PSMA to Those That Will Most Benefit?
- Details
(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL between May 30 and June 3 was host to the Session State of the Art Lecture: Personalizing treatment for patients with metastatic castration resistant prostate cancer (mCRPC) in 2025. Dr. Ruben Raychaudhuri delivered a presentation discussing How to Get Lutetium-177 PSMA to Those That Will Most Benefit?
ASCO 2025: Discussion: Tailoring Therapy in Castration-Sensitive Prostate Cancer: Do Biomarkers Make the Cut?
- Details
(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL between May 30 and June 3 was host to the Oral Abstract Session: Genitourinary Cancer—Prostate, Testicular, and Penile. Dr. Rahul Raj Aggarwal delivered a presentation titled: Tailoring Therapy in Castration-Sensitive Prostate Cancer: Do Biomarkers Make the Cut?
ASCO 2025: Radioligand Therapies in Prostate Cancer: Hits, Misses, and Next Steps
- Details
(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL between May 30th and June 3rd, 2025, was host to a New Frontiers in Prostate-Specific Membrane Antigen (PSMA) Radioligand Therapy. Dr. Jorge Garcia discussed ‘hits, misses, and next steps’ in prostate cancer radioligand therapies.
ASCO 2025: Trials-in-Progress: Precision Diagnostics in Prostate Cancer Treatment (PREDICT): A Phase 2 Multi-Arm Biomarker-Based Study (Alliance A032102)
- Details
(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL between May 30th and June 3rd, 2025, was host to a prostate, testicular, and penile cancers poster session. Dr. Rana McKay presented the ongoing PREDICT (PREcision Diagnostics in Prostate Cancer Treatment) trial, a phase II, multi-arm, biomarker-based study (Alliance A032102).
ASCO 2025: Intravesical Disitamab Vedotin (RC48) for Patients with HER2-Expressing High-Risk Non-Muscle-Invasive Bladder Cancer: A Dose-Escalation Phase I Trial
- Details
(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL between May 30th and June 3rd, 2025, was host to a kidney and bladder cancers poster session. Dr. Xu Chen presented the results of a dose-escalation phase I trial evaluating intravesical disitamab vedotin (RC48) for patients with HER-2 expressing high-risk, non-muscle invasive bladder cancer (NMIBC).
ASCO 2025: First-in-Human Results of Terbium-161 161Tb-PSMA-I&T Radioligand Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer (VIOLET): A Single-Centre, Single-Arm, Phase I/II Study
- Details
(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL between May 30 and June 3 was host to the Session New Frontiers in Prostate-Specific Membrane Antigen Radioligand Therapy. Dr. Michael Hofman presented the First-in-human results of terbium-161 161Tb-PSMA-I&T radioligand treatment in patients with metastatic castration-resistant prostate cancer (VIOLET): A single-centre, single-arm, phase I/II study.
ASCO 2025: STARLITE-1: Phase 1b/2 Study of Combination 177Lu Girentuximab plus Cabozantinib and Nivolumab in Treatment Naive Patients with Advanced Clear Cell RCC
- Details
(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL between May 30 and June 3 was host to the Poster Session: Genitourinary Cancer - Kidney and Bladder. Dr. Eric Jonasch presented the trial in progress Poster TPS4611: STARLITE-1: Phase 1b/2 study of combination 177Lu girentuximab plus cabozantinib and nivolumab in treatment naive patients with advanced clear cell RCC.
ASCO 2025: Assessing Treatment Outcomes of Enfortumab Vedotin Dose Reduction in Metastatic Bladder Cancer
- Details
(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL between May 30 and June 3 was host to the Poster Session: Genitourinary Cancer - Kidney and Bladder. Dr. Hal Difede Rives presented Poster 4576: Assessing treatment outcomes of enfortumab vedotin dose reduction in metastatic bladder cancer.
ASCO 2025: COBRA: Assessment of the Efficacy of 64Cu-SAR-bisPSMA Using Histopathology and Standard of Care Imaging as Reference Standard in Patients with Biochemical Recurrence of Prostate Cancer Following Definitive Therapy
- Details
(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL between May 30 and June 3 was host to the Poster Session: Genitourinary Cancer - Prostate, Testicular, and Penile Cancer. Luke Nordquist, MD, FACP, presented Poster 5102: COBRA: Assessment of the efficacy of 64Cu-SAR-bisPSMA using histopathology and standard of care imaging as reference standard in patients with biochemical recurrence of prostate cancer following definitive therapy.
ASCO 2025: Safety and Pharmacokinetics of Mevrometostat in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer
- Details
(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL between May 30 and June 3 was host to the Poster Session: Genitourinary Cancer - Prostate, Testicular, and Penile Cancer. Dr. Nobuaki Matsubara presented Poster 5046: Safety and pharmacokinetics of mevrometostat in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC).
ASCO 2025: Parp Up the Volume!: Combination Strategies in Advanced Prostate Cancer
- Details
(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL, was host to the Oral Abstract Session: Genitourinary Cancer—Prostate, Testicular, and Penile. Dr. Joaquin Mateo delivered a lecture titled: Parp Up the Volume!: Combination Strategies in Advanced Prostate Cancer.
ASCO 2025: Discussion: Better Treatments, Better Selection: Improving Patient Outcomes in Localized Prostate Cancer
- Details
(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL, was host to the Oral Abstract Session: Genitourinary Cancer—Prostate, Testicular, and Penile. Dr. Angela Jia discussed How Better Treatments and Better Selection Can Improve Patient Outcomes in Localized Prostate Cancer.
ASCO 2025: Multimodal Artificial Intelligence (MMAI) Model to Identify Benefit from 2nd-Generation Androgen Receptor Pathway Inhibitors (ARPI) in High-Risk Non-Metastatic Prostate Cancer Patients from STAMPEDE
- Details
(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL, was host to the Oral Abstract Session: Genitourinary Cancer—Prostate, Testicular, and Penile. Dr. Nicholas James presented a study assessing a multimodal artificial intelligence (MMAI) model to identify benefit from 2nd-generation androgen receptor pathway inhibitors (ARPI) in high-risk non-metastatic prostate cancer patients from STAMPEDE.
ASCO 2025: Non-Androgen-Receptor–Driven Prostate Cancer: Updates in Biology, Classification, and Management
- Details
(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL, was host to the Session State of the Art Lecture: Personalizing treatment for patients with metastatic castration resistant prostate cancer (mCRPC) in 2025. Dr. Himisha Beltran delivered a presentation on Non-Androgen-Receptor–Driven Prostate Cancer: Updates in Biology, Classification, and Management.
ASCO 2025: Transcriptome Classification of PTEN Inactivation to Predict Survival Benefit from Docetaxel at Start of Androgen Deprivation Therapy (ADT) for Metastatic Prostate Cancer (PC): An Ancillary Study of the STAMPEDE Trials
- Details
(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL, was host to the Oral Abstract Session: Genitourinary Cancer—Prostate, Testicular, and Penile. Dr. Emily Grist presented an ancillary study of the STAMPEDE trials evaluating if Transcriptome classification of PTEN inactivation predicts survival benefit from docetaxel at the start of androgen deprivation therapy (ADT) for metastatic prostate cancer.
ASCO 2025: Phase 3 AMPLITUDE Trial: Niraparib and Abiraterone Acetate plus Prednisone for Metastatic Castration-Sensitive Prostate Cancer Patients with Alterations in Homologous Recombination Repair Genes
- Details
(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, held in Chicago, IL, was host to the Oral Abstract Session: Genitourinary Cancer—Prostate, Testicular, and Penile. Dr. Gerhardt Attard presented the Phase 3 AMPLITUDE trial: Niraparib and abiraterone acetate plus prednisone for metastatic castration-sensitive prostate cancer patients with alterations in homologous recombination repair genes.